[HTML][HTML] KRAS mutations in advanced non-small cell lung cancer: from biology to novel therapeutic strategies
Kristen rat sarcoma viral oncogene homolog (KRAS) mutations play a major role in the
carcinogenesis of many types of solid tumors including non-small cell lung cancer (NSCLC) …
carcinogenesis of many types of solid tumors including non-small cell lung cancer (NSCLC) …
Targeting KRAS: from metabolic regulation to cancer treatment
Y Shi, H Zheng, T Wang, S Zhou, S Zhao, M Li, B Cao - Molecular Cancer, 2025 - Springer
The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic
role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored …
role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored …
[HTML][HTML] Breakthrough in RAS targeting with pan-RAS (ON) inhibitors RMC-7977 and RMC-6236
The multi-selective tri-complex RAS (ON) inhibitors RMC-7977 and RMC-6236 signal new
avenues for RAS targeting. This systematic review aims to comprehensively present the …
avenues for RAS targeting. This systematic review aims to comprehensively present the …
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives
Q He, X Liu, L Jiang, P Liu, W Xuan… - Cancer Biology & …, 2025 - Taylor & Francis
ABSTRACT KRAS mutations are common in non-small cell lung cancer (NSCLC) and are
associated with patient prognosis; however, targeting KRAS has faced various difficulties …
associated with patient prognosis; however, targeting KRAS has faced various difficulties …
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
M Kramer‐Drauberg, E Petrini, A Mira… - Molecular …, 2025 - Wiley Online Library
Specific reactive oxygen species activate the GTPase Kirsten rat sarcoma virus (KRAS) by
reacting with cysteine 118 (C118), leading to an electron transfer between C118 and …
reacting with cysteine 118 (C118), leading to an electron transfer between C118 and …
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
ATM Lee, M Nagasaka - Lung Cancer: Targets and Therapy, 2024 - Taylor & Francis
Abstract Mutations in KRAS G12C are among the more common oncogenic driver mutations
in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug …
in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug …
[HTML][HTML] Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR-and KRAS-Mutant Non-Small …
L Amato, D Omodei, C De Rosa, A Ariano, S Capaldo… - Cancers, 2024 - mdpi.com
Background: Oncogene-driven NSCLC is usually treated with targeted therapies using
tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways …
tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways …
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
AE Maciag, JP Stice, B Wang, AK Sharma… - Cancer …, 2025 - aacrjournals.org
Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the
inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP …
inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP …
Ductal pancreatic cancer interception by FGFR2 abrogation
Activating KRAS mutations are a key feature of pancreatic ductal adenocarcinoma (PDA)
and drive tumor initiation and progression. However, mutant KRAS by itself is weakly …
and drive tumor initiation and progression. However, mutant KRAS by itself is weakly …
Direct measurement of PIP2 densities in biological membranes using a peptide-based sensor
VK Menon, J Wu, A Alonzo, K Rogers, KL Scrudders… - bioRxiv, 2024 - biorxiv.org
Organization and composition of the plasma membrane are important modulators of many
cellular programs. Phosphatidylinositol phosphate (PIP) lipids are low abundance …
cellular programs. Phosphatidylinositol phosphate (PIP) lipids are low abundance …